

# KAPPAC PHARMA LIMITED

CIN NO: L24230MH1981PLC025002

E mail: [kappacpharma@yahoo.com](mailto:kappacpharma@yahoo.com)

Through E Mail

Date: 15.03.2021

To,  
Department of Corporate Services,  
**BSE Limited**  
P. J. Towers, Dalal Street,  
Mumbai- 400001

Dear Sir,

**Sub: Submission of Disclosures under Regulation 29 (1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 – Details of acquisition of 5% or more shares in a listed company.**


**Ref: Scrip Code: 539833 Scrip ID: SICLTD**

We are sending herewith Disclosures under Regulation 29 (1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 – Details of acquisition of 5% or more shares in a listed company.

Please find above in order and acknowledge the same.

Thanking You,

Yours faithfully,  
FOR, KAPPAC PHARMA LIMITED

  
DIRECTOR/ AUTHORIZED SIGNATORY  
AUTHORISED SIGNATORY

Encl: As above.

C.C

To,


Compliance Officer  
SHIVOM INVESTMENT & CONSULTANCY LTD  
Shop No. 10, MMRDA Market,  
Thakur Complex, Kandivali East,  
Mumbai, Maharashtra, 400101  
E mail: [shivomicl@gmail.com](mailto:shivomicl@gmail.com)



**Disclosures under Regulation 29(1) of  
SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**Part-A- Details of the Acquisition**

|   |  |   |  |
|---|--|---|--|
| Name of the Target Company (TC)   | <b>SHIVOM INVESTMENT &amp; CONSULTANCY LIMITED<br/>(BSE Security Code: 539833)</b> |   |  |
| Whether the acquirer/seller belongs to Promoter/Promoter group  | <b>KAPPAC PHARMA LIMITED</b>   |   |  |
| Whether the acquirer/seller belongs to Promoter/Promoter group  | <b>No</b>  |   |  |
| Name(s) of the Stock Exchange(s) where the shares of TC are Listed  | <b>BSE Limited</b>   |   |  |
| Details of the acquisition as follows   | Number   | Number % w.r.t. total share/voting Capital wherever applicable(*) | % w.r.t. total diluted share/voting capital of the TC (**) |
| <b>Before the acquisition/<del>disposal</del> under consideration, holding of acquirer along with PACs of:</b>  |  |   |  |
| a) Shares carrying voting rights  | <b>29,86,500</b>   | <b>4.27</b>   | <b>4.27</b>  |
| b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)   | <b>00</b>  | <b>00</b>   | <b>00</b>  |
| c) Voting rights (VR) otherwise than by equity shares   | <b>00</b>  | <b>00</b>   | <b>00</b>  |
| d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC(specify holding in each category) | <b>00</b>  | <b>00</b>   | <b>00</b>  |
| <b>e) Total (a+b+c+d)</b>   | <b>29,86,500</b>   | <b>4.27</b>   | <b>4.27</b>  |
| <b>Details of Acquisition/Sale</b>  |  |   |  |
| a) Shares carrying voting rights acquired   | <b>46,48,172</b>   | <b>6.64</b>   | <b>6.64</b>  |
| b) VRs acquired otherwise than by equity shares   | <b>00</b>  | <b>00</b>   | <b>00</b>  |
| c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying category) acquired  | <b>00</b>  | <b>00</b>   | <b>00</b>  |
| d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)   | <b>00</b>  | <b>00</b>   | <b>00</b>  |
| <b>e) Total (a+b+c+/-d)</b>   | <b>46,48,172</b>   | <b>6.64</b>   | <b>6.64</b>  |





| <b>Details of Acquisition/Sale</b>  |  |              |              |
|---|--|--------------|--------------|
| a) Shares carrying voting rights  | <b>76,34,672</b>   | <b>10.91</b> | <b>10.91</b> |
| b) VRs otherwise than by equity shares  | <b>00</b>  | <b>00</b>    | <b>00</b>    |
| c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition      | <b>00</b>  | <b>00</b>    | <b>00</b>    |
| d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)   | <b>00</b>  | <b>00</b>    | <b>00</b>    |
| <b>e) Total (a+b+c+d)</b>   | <b>76,34,672</b>   | <b>10.91</b> | <b>10.91</b> |
| Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)   | <b>Off Market</b>  |              |              |
| Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.   | <b>NA</b>  |              |              |
| Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC. | <b>15.03.2021</b>  |              |              |
| Equity share capital / total voting capital of the TC before the said acquisition   | <b>Rs. 69,95,13,250/- divided in to 6,99,51,325 Equity share of Rs. 10/- each.</b> |              |              |
| Equity share capital/ total voting capital of the TC after the said acquisition   | <b>Rs. 69,95,13,250/- divided in to 6,99,51,325 Equity share of Rs. 10/- each.</b> |              |              |
| Total diluted share/voting capital of the TC after the said acquisition   | <b>Rs. 69,95,13,250/- divided in to 6,99,51,325 Equity share of Rs. 10/- each.</b> |              |              |

**KAPPAC PHARMA LIMITED**



**DIRECTOR/AUTHORISED SIGNATORY**